Dr. Rohit Mukhi and the experienced professionals at Buford Family Dental provide a wide menu of services, including general, pediatric, restorative and cosmetic dentistry, as well as orthodontics (OrthoFX™).
BUFORD, Ga., Aug. 16, 2023 /PRNewswire-PRWeb/ — At Buford Family Dental in Buford, Georgia, their mission is to provide the very best in affordable, comprehensive dental care for the entire family at their state-of-the-art clinic. The team is proud to now offer OrthoFX™ aligners, which are the latest in orthodontic innovation and can give adult patients a brand-new smile in as little as six to eighteen months. OrthoFX is a clear aligner system (no brackets or bands) that uses the latest in orthodontic advances to straighten teeth quickly, comfortably and effectively. The system consists of a series of clear polymer aligners that are custom-made to fit teeth. The aligners are worn for 20 to 22 hours per day and are removed only for eating, drinking, brushing and flossing. As patients progress through the series of aligners, teeth will gradually move into their new, straighter positions. Orthodontic treatment can improve the appearance, alignment and function of the smile. It can also help to prevent or reduce future problems with the teeth and jaw. The OrthoFX system is an affordable alternative to other clear aligner systems, and the polymer material doesn’t stain like aligners made from plastic. Beyond these advantages, OrthoFX accelerates treatment progress by providing new aligners on a weekly basis (rather than bi-weekly), and the process is monitored by AI to ensure accuracy and predictability. At Buford Family Dental, they are always on the cutting edge with modern dentistry, comfortable amenities, easy scheduling options, emergency dental care, same-day appointments and insurance plan acceptance.
Achieving a remarkable 100% increase in new customers quarter over quarter, leading to a 175% growth in BRR revenue.
Recording an exceptional 175% upswing in engagement hours.
And building a thriving talent network of over 1200 health IT professionals.
This impressive growth is a testament to Revuud’s dedication to revolutionizing how healthcare organizations find, hire, and manage their IT talent. Among its success stories, Revuud is proud to announce that one of the largest healthcare organizations in the country has licensed Revuud as part of their initiative to transform their IT workforce management processes. Additionally, Revuud is honored to provide its cutting-edge services to a globally acclaimed teaching hospital, reaffirming its commitment to fostering excellence in healthcare IT.
Revuud’s Co-Founder, Eric Utzinger expresses immense gratitude for the trust that healthcare entities have placed in Revuud’s platform. “Our growth reflects our relentless drive to address the evolving needs of the healthcare industry. We are excited to empower healthcare organizations with innovative tools that streamline talent acquisition and optimize workforce management.”
Co-founder and CEO Dan Schubert adds: “The future looks brighter than ever for Revuud as it continues to shape the future of healthcare IT staffing, setting new industry standards and empowering healthcare organizations with unparalleled workforce solutions.”
About Revuud
Revuud is a leading healthcare IT staffing marketplace that helps healthcare organizations connect with top engineering talent. Our mission is to revolutionize the way healthcare organizations hire IT talent by providing a faster, more efficient, and cost-effective solution. With our platform, healthcare organizations can easily search and connect with IT candidates, review their portfolios, and evaluate their credentials and references, all in one place. For more information, please visit http://www.revuud.com.
DUBLIN, Aug. 15, 2023 /PRNewswire/ — The “South Africa Biopharmaceuticals Market – Industry Outlook & Forecast 2023-2028” report has been added to ResearchAndMarkets.com’s offering. South Africa biopharmaceuticals market is poised to achieve remarkable milestones, anticipating an…
“We are honored to partner with the Missouri DSDS in deploying the Medicaid case management system for Home and Community-Based Services programs,” said VIP CEO, Jonna Ward. “This innovative solution will empower the department to deliver personalized care efficiently and effectively to thousands of participants across the state. Through our collaboration, we aim to enhance the lives of Missouri’s aging and disabled population, enabling them to thrive in their homes and communities.”
The ECMS system will offer end-to-end case tracking for both Medicaid State Plan (MSP) Services and Waiver programs. This new system will include seamless participant assessments, personalized service plans, integrated data tracking, an online portal, as well as advanced analytics.
About VIP
VIP helps its clients strengthen mission outcomes by combining deep industry specialization, agility to adapt as needed, and an unwavering commitment to client satisfaction. VIP empowers clients to modernize systems and experiences with leading technology solutions through our systematic and repeatable system integration and time-tested delivery methodology. VIP addresses the complexity of digital transformation nationwide for customers such as the California Department of Consumer Affairs, Virginia Department of Medical Assistance Services, Oregon Department of State Lands, Nevada Department of Public Safety, and Fairfax County. Since 1996, VIP has worked with over 1,200 public sector and commercial clients. For more information, please visit‥https://trustvip.com.
About Missouri Division of Senior and Disability Services (DSDS)
DSDS acts as the designated state unit on aging, carrying out the mandates of the state of Missouri regarding programs and services for seniors and adults with disabilities. DSDS is responsible for the development and implementation of programs designed to protect seniors and adults with disabilities and for the administration of an integrated system of care for eligible adults that require long-term care. In addition to the HCBS program DSDS operates Adult Protective Services, Long-term Care Ombudsman Program, Money Follow the Person Program and a variety of other senior programs.
Alexis Colvin, MD, Professor of Orthopedics at the Icahn School of Medicine at Mount Sinai, continues her dual roles as Chief Medical Officer of the US Open and U.S. Billie Jean King Cup Team Physician. She is joined this year by Melissa Leber, MD, Associate Professor of Orthopedics, and Emergency Medicine, at Icahn Mount Sinai, who has been appointed Director of Player Medical Services of the US Open by the USTA. Drs. Colvin and Leber will lead a team of renowned orthopedic surgeons, sports medicine physicians, emergency medicine physicians, musculoskeletal radiologists, and other specialists from Mount Sinai. James Gladstone, MD, Chief of the Sports Medicine Service and Associate Professor of Orthopedics at Icahn Mount Sinai, continues as the official U.S. Davis Cup Team Physician, in addition to supporting the Player Medical Services team at the US Open.
“We are honored to bring our multidisciplinary team of medical experts together to provide outstanding comprehensive health care for all of the athletes for the 11th consecutive year,” said Dr. Colvin. “I am proud to serve alongside Dr. Leber in her new role. It speaks volumes about the importance of diversity and inclusion in professional sports to have two women leading medical care at an internationally recognized sporting event. Along with the entire medical team from Mount Sinai, we bring years of sports medicine expertise grounded in innovative research to the tournament.”
Dr. Colvin is the first Asian American and first woman to hold the title of Chief Medical Officer at the US Open, a role she has held for a decade. She is a board certified orthopedic and sports medicine surgeon who has served as a physician at the U.S. Olympic and Paralympic Training Center. She presides on the board of the Hologic WTA Women’s Health Taskforce and also supports non-profit organizations dedicated to improving girls’ participation in sports.
Dr. Leber is a registered musculoskeletal sonographer with many years of experience in diagnostic ultrasound and ultrasound-guided procedures. This expertise makes her a leader in the field of sports medicine, helping her to achieve more targeted and effective results in returning athletes of all ages to their sport and activity. She has also worked as a physician, medical liaison, and consultant for professional basketball and football teams and leagues in the United States.
“I am thrilled to be the new Director of Player Medical Services for the US Open,” said Dr. Leber. “Our team of health care experts who serve this tournament provide all US Open competitors with the highest-quality care, including the junior and wheelchair athletes. I look forward to working alongside Drs. Colvin and Gladstone to support professional tennis at this Grand Slam event.”
“Mount Sinai has been an incredibly vital partner for more than 10 years, setting industry standards for player health care at the US Open,” said Stacey Allaster, US Open Tournament Director and Chief Executive of Professional Tennis for the USTA. “Continuing this partnership strengthens our ability to deliver on our shared priorities. Together we provide best-in-class care and services for US Open players and our Billie Jean King and Davis Cup Teams, and we spread the message that tennis is an ideal sport for health and longevity.”
In addition to providing medical services for the 2023 US Open, Mount Sinai will engage fans and families at an interactive booth onsite at the USTA Billie Jean King National Tennis Center throughout the tournament and Fan Week, at the Mount Sinai Children’s Sports Zone court on Arthur Ashe Kids’ Day, and via digital and social media, sweepstakes, giveaways, and photo experiences. Mount Sinai will also host two professional tennis players for special meet-and-greet appearances onsite, and will announce the talent, dates, and locations prior to both events. Mount Sinai will further showcase the Health System’s commitment to diversity and inclusion through a vibrant new promotional campaign, “Serving All: Championing Advanced, Equitable Health Care.” For more information about Mount Sinai’s 2023 activities and USTA partnership, please visit: https://www.mountsinai.org/usopen.
Mount Sinai clinicians supporting the 2023 US Open include the following faculty members at Icahn Mount Sinai, plus other physicians, specialists, consultants, and medical staff:
Shawn Anthony, MD, MBA, Associate Chief of Sports Medicine Service; Assistant Professor of Orthopedics
Carlos Benitez, MD, Director of Musculoskeletal Imaging at Mount Sinai West; Associate Professor of Diagnostic, Molecular, and Interventional Radiology
Alexis Colvin, MD, Chief Medical Officer for the US Open; U.S. Team Physician for the Billie Jean King Cup; Professor of Orthopedics; Senior Associate Dean for Alumni Affairs
Houman Danesh, MD, Associate Professor of Anesthesiology, Perioperative and Pain Medicine, and Rehabilitation and Human Performance
Elizabeth Dennis, MD, Assistant Professor of Orthopedics
James Gladstone, MD, U.S. Team Physician for the Davis Cup; Chief of Sports Medicine Service; Associate Professor of Orthopedics
Chen He, MD, Assistant Professor of Emergency Medicine
Tom Hildebrandt, PsyD, Professor of Psychiatry
Melissa Leber, MD, Director of Player Medical Services for the US Open; Associate Professor of Orthopedics, and Emergency Medicine
James Mattson, MD, Assistant Professor of Emergency Medicine, and Rehabilitation and Human Performance
Justin Ngeow, MD, Assistant Professor of Diagnostic, Molecular, and Interventional Radiology
Trevor Pour, MD, Associate Professor of Emergency Medicine
Christopher Reverte, MD, Assistant Professor of Emergency Medicine
Aruna Seneviratne, MD, Associate Professor of Orthopedics
Eric Small, MD, Clinical Assistant Professor of Pediatrics, and Orthopedics
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals” and by U.S. News & World Report’s® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report’s® “Best Hospitals” Honor Roll for 2023-2024.
About the United States Tennis Association
The USTA is the national governing body for the sport of tennis in the U.S. and the leader in promoting and developing the growth of tennis at every level — from local communities to the highest level of the professional game. A not-for-profit organization, it invests 100% of its proceeds in growing the game. It owns and operates the US Open, one of the highest-attended annual sporting events in the world, and launched the US Open Series, linking summer WTA and ATP World Tour tournaments to the US Open. In addition, it owns approximately 120 Pro Circuit events throughout the U.S. and selects the teams for the Davis Cup, Billie Jean King Cup, Olympic and Paralympic Games. The USTA’s philanthropic entity, the USTA Foundation, provides grants and scholarships in addition to supporting tennis and education programs nationwide to benefit under-resourced youth through the National Junior Tennis & Learning (NJTL) network. For more information about the USTA, go to USTA.com or follow the official accounts on Facebook, Instagram, Twitter (X), and TikTok.
Veterinary Experts Discuss How to Detect, Diagnose Periodontal Disease
LOUIS, Ky., Aug. 14, 2023 /PRNewswire-PRWeb/ — Pets often don’t outwardly show they are in pain, but specific behaviors may help pet owners seek out medical help. This September, for Animal Pain Awareness Month, the expert advisors for OraStripdx are calling attention to the pain associated with periodontal disease, which begins as an invisible infection of the gums and eventually develops into a very painful condition, affecting 80 to 90 percent of cats and dogs. OraStripdx is a revolutionary 10-second test that detects even the earliest stage of periodontal disease in pets.
“Dental pain is one of the least recognized forms of pain, but it’s the most impactful on a pet’s quality of life,” said Dr. Wendy Hauser, OraStripdx’s chief veterinary consultant, founder of Peak Veterinary Consulting, and a veterinarian with more than 30 years of experience. “Animals’ instinctive reaction is to eat even if they are in pain. However, pet owners can prevent much of that pain if they recognize subtle behavior changes indicating their pet isn’t feeling well.”
Signs a Pet Has Oral Pain
1. Changes in eating habits. Often, swallowing food whole is a sign that pets have oral pain, but some pets rarely chew their food, so pets owners should look for changes in behavior rather than specific behaviors. “A pet who previously ate quickly may eat slowly, or chew on just one side of their mouth,” said Kara Burns, a veterinary nurse and editor-in-chief of Today’s Veterinary Nurse.
2. Changes in social behavior. Mary Berg, a sought-after veterinary dental technician educator, and president of Beyond the Crown Veterinary Education, recalled an instance where a cat was attacking the family’s children. “Once we diagnosed and treated the periodontal disease with a tooth extraction, the cat resumed its loving demeanor,” said Berg. Quiet and calm behavior can also hide pain. “A man who adopted a quiet, calm dog brought him in for a dental exam. Once we cleaned up the areas that caused him pain, the dog became much more active – and the man asked us to put his teeth back – as a joke of course!” A dog slowing down at a young age, a cat who is less willing to interact and a pet who no longer wants to retrieve a ball are all potential signs of pain and oral disease.
3. Sleeping changes. After performing a tooth extraction on a dog, the pet’s owner told Dr. Hauser the pet was no longer waking up in the middle of the night. “We realized, after the fact, that the dog was waking up in pain,” said Hauser. “Noticing changes in sleep habits could help pets get medical treatment earlier.”
4. Drooling, halitosis. Drooling and halitosis (bad breath) are more noticeable indicators of periodontal disease. “If your pet has bad breath or is drooling, it’s a definite sign they should come in for an exam,” said Berg. “Most owners bring their pets in at this stage, but it’s likely they’re already in pain caused by periodontal disease.”
Hauser, Burns, and Berg are all expert advisors for OraStripdx, which can be administered with no anesthesia or sedation required. When the test is gently swiped along the gumline of a dog or cat, thiols in the oral fluid will cause it to change color with the concentration of thiols, reflecting periodontal disease activity.
Recommended for use in every wellness exam, OraStripdx helps veterinary teams identify periodontal disease before it causes major pain in dogs and cats, and provides visual evidence to support their recommendations for treatment and home care. Studies have shown the test to increase client compliance by over 50%.
Studies and scientific information about OraStripdx are available on the product’s website, orastripdx.com.
# # #
About OraStripdx and PDX BIOTECH Manufactured in the U.S., OraStripdx is the premier product developed and produced by PDX BIOTECH, a growth-stage biotechnology company based in Louisville, Kentucky. The company is comprised of a core team of seasoned scientists and business leaders having over a century of combined experience, as well as an advisory board of global thought-leader veterinary clinicians. With the distribution of OraStripdx, PDX BIOTECH intends to contribute every day to the long-term health and wellness of pets and their families worldwide.
Global law firm Greenberg Traurig, LLP Shareholders Dr. Melissa Hunter-Ensor and Chia-Feng Lu are shortlisted to receive LMG Life Sciences 2023 Americas Awards.
Boston, Aug. 14, 2023 /PRNewswire-PRWeb/ — Global law firm Greenberg Traurig, LLP Shareholders Dr. Melissa Hunter-Ensor and Chia-Feng Lu are shortlisted to receive LMG Life Sciences 2023 Americas Awards. Winners will be announced at an event to be held in New YorkSept. 7. Last year, David J. Dykeman, co-managing shareholder of the firm’s Boston office and co-chair of the firm’s Global Life Sciences & Medical Technology Group, was an honoree.
Hunter-Ensor, who is co-chair of the firm’s global Patent Prosecution Practice, is shortlisted for Patent Strategy Attorney of the Year – Massachusetts. Lu, who is a shareholder in the firm’s Health Care & FDA Practice and Life Sciences & Medical Technology Group, is shortlisted for U.S. Rising Star – Regulatory.
LMG Life Sciences is considered one of the definitive guides to leading U.S., Canada, Europe, Middle East, and Africa law firms and lawyers specializing in the life sciences industry. The guide’s LMG Life Sciences Awards recognize key law firms, lawyers, and the innovative work accomplished throughout the life sciences industry. They are based on marketplace and client feedback, as well as information provided by firms, which can only be ranked if the market deems them worthy of consideration.
Hunter-Ensor focuses her practice on the intellectual property (IP) and commercial needs of clients in the life sciences industry, encompassing pharmaceutical, biotechnology, chemical, agricultural, diagnostics, and medical device companies. She has experience representing clients throughout the business cycle, from startups and universities to global pharmaceutical companies, patent portfolio management, and strategic alliances, as well as litigation and pre-litigation strategy. Hunter-Ensor also assists venture capital firms and other investors in assessing the IP risks of target investments and conducts IP patent and licensing due diligence in connection with complex life science technology transactions.
Lu guides life sciences and emerging technology companies, as well as industry associations, through the regulatory and transactional law surrounding life sciences and emerging technologies. He represents companies in strategic regulatory and legislative processes before various government agencies, to guide and develop new legislation and policy, to frame effective approaches to working with the various agencies on compliance and investigation issues, and to help clients develop strategic plans to obtain the regulator’s favorable view on their innovative products or ideas. This includes providing counsel on the development and commercialization of novel technology products, such as cell therapy, cancer immunotherapy, mobile health and digital health products, microorganism, precision medicine-related products and services, regenerative medicine, 3D-printing, etc. Among all his representations, Lu has been involved in several products based on Nobel-winning science in the past two decades respectively, and one of them has successfully reached the blockbuster status.
About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from start-ups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig: Greenberg Traurig, LLP has more than 2650 attorneys in 45 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2022 BTI “Highly Recommended Law Firm” for superior client service and is consistently among the top firms on the Am Law Global 100 and NLJ 500. Greenberg Traurig is Mansfield Rule 5.0 Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA’s Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: http://www.gtlaw.com.
In this free webinar on long-acting injectables, learn about the selection and optimization of long-acting microsphere formulations with releases ranging from weeks to one year, applying a diverse portfolio of bioresorbable polymers to a unique polymer-based injectable microsphere platform.
TORONTO, Aug. 14, 2023 /PRNewswire-PRWeb/ — Register for this webinar on long-acting injectables and learn about the selection and optimization of long-acting microsphere formulations with releases ranging from weeks to one year, applying a diverse portfolio of bioresorbable polymers to a unique polymer-based injectable microsphere platform.
The presentation will showcase the selection and optimization of long-acting microsphere formulations with releases ranging from weeks to one year, applying Ashland’s Viatel™ polymer portfolio to Oakwood Laboratories’ Chroniject™ platform. Ashland and Oakwood Laboratories will present together, respectively discussing the chemistry of bioresorbable polymers applied to various parenteral formulations and a microsphere technology platform that offers reproducible, scalable and consistent critical quality attributes under cGMP for multiple therapeutic indications.
Ashland will show how understanding the chemistry and versatility of Viatel™ polymers helps solve challenges in controlled drug release formulations and medical devices. Ashland will also introduce their NEW Viatel™ Ultrapure polymer grades and detail the advantages of ultra-low (≤ 0.5%) residual monomer specifications.
Oakwood Laboratories will present two small molecule active pharmaceutical ingredient (API) microsphere case studies, (1) from formulation development through scale up and (2) highlighting common scale-up challenges and solutions. They showcase how varying process parameters and polymer chemistries based on lactide and glycolide make it possible to optimize drug load, release duration, particle size and encapsulation efficiency.
Join Seán McMahon, PhD, Global Business Manager – Injectables, Life Sciences, Ashland; and Rachel Galaska, Formulation Engineer, R&D, Oakwood Laboratories, for the live webinar on Wednesday, September 6, 2023, at 10am EDT (4pm CEST/EU-Central).
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Ashland will show how understanding the chemistry and versatility of Viatel™ polymers helps solve challenges in controlled drug release formulations and medical devices.
SEOUL, South Korea, Aug. 14, 2023 /PRNewswire/ — ROKIT HEALTHCARE, a pioneering biotech firm specializing in advanced organ regeneration, proudly announces a significant milestone. In July 2023, the company obtained the coveted certification under the European Medical Device Regulation…
Funding will support continuation of work started by Galas and Lisa Stubbs, Ph.D., to identify genetic factors influencing the brain’s response to stress
SEATTLE, Aug. 10, 2023 /PRNewswire-PRWeb/ — Washington Research Foundation (WRF) has awarded a $100,000 grant to Pacific Northwest Research Institute (PNRI) in honor of David J. Galas, Ph.D., who helped to create the WRF Postdoctoral Fellowship program in 2017 and served on the WRF board of directors from 2010 until his death in May. The grant will support the continuation of work begun by Galas and his colleague Lisa Stubbs, Ph.D., investigating the genetic links between stress and a range of health disorders.
Galas was a renowned expert in molecular biology and human genetics. He was a leader in the Human Genome Project and a key contributor to the technology that enabled one of the earliest rapid tests for COVID-19. In 2012, he joined PNRI as a senior investigator.
Inspired to apply his novel computational approaches to find ways to improve the human condition, Galas, together with PNRI senior investigator Stubbs, launched the groundbreaking Decoding Stress Study in 2021. The goal of the study is to pinpoint the exact genes, gene networks and patterns of mutations responsible for how humans’ brains and bodies respond to chronic stress and to identify how an individual’s unique genetic makeup contributes to their risk of developing stress-related diseases, such as anxiety, depression, type 2 diabetes and heart disease.
Galas and his team focused on developing and applying innovative mathematical methods, providing new computational tools to seek out and validate genetic interactions significant to this research. The findings of the Decoding Stress Study will ultimately provide the basis for new genetic screens to identify people who are at the greatest risk of developing stress-related disease, as well as to guide doctors in choosing the right treatment for each person.
With support from WRF’s grant, Stubbs will continue to lead this project.
“We are honored to continue pursuing David’s vision—that of using an individual’s unique genetic make-up to identify those at greatest risk of stress-related diseases—with the goal of developing tailored therapies to identify and treat them. This is David’s legacy gift to all humanity,” said Stubbs.
In addition to his roles with PNRI and WRF, Galas was chair of the Hertz Foundation board of directors, a lifetime National Associate of the National Academy of Sciences, and an entrepreneur who held 20 issued U.S. patents and authored more than 180 scientific publications. He was also an accomplished artist and poet.
Brooks Simpson, WRF’s board chair, said, “David was an incredible board member and mentor to all of us. We are better board members, stronger staff and an enriched organization because of him. As an example, David’s insight and belief in postdocs led to the creation of our fellowship program. That will always remain a hallmark of our contributions to the research engines in the region.”
“WRF’s generous gift is a profound testament to David, who never stopped discovering and pushed the boundaries of our knowledge about genetics right up to the end of his life,” said Diane Isonaka, Galas’ widow. “This gift will ensure that the innovative methods and tools that David introduced in the Decoding Stress Study will continue to shape the field of genetics and benefit generations to come with improved healthcare, personalized treatments and a deeper understanding of life itself.”
###
About Pacific Northwest Research Institute:
Pacific Northwest Research Institute (PNRI) is a nonprofit biomedical research institute, where scientists use innovative approaches in genetics and genomics to tackle some of the most difficult problems in science and medicine. The institute was founded 67 years ago in Seattle, Washington, as a place where scientists were free to pursue discoveries that promised the highest chance of improving human health. The goal was at the beginning, and remains today, to conduct foundational science that drives future medical innovations. To learn more, visit pnri.org.
About Washington Research Foundation:
Washington Research Foundation (WRF) supports research and scholarship in Washington state, with a focus on life sciences and enabling technologies. WRF was founded in 1981 to assist universities and other nonprofit research institutions in Washington with the commercialization and licensing of their technologies. WRF is one of the foremost technology transfer and grant-making organizations in the nation, having earned more than $445 million in licensing revenue for the University of Washington and providing over $147 million in grants to the state’s research institutions to date.
WRF Capital, the investment vehicle for Washington Research Foundation, has backed 122 local startups since 1996. Returns support the Foundation’s investment and grant-making programs.
For additional information, please visit wrfseattle.org.
Media Contact
Dale Wadman, Washington Research Foundation, (206) 336-5600, [email protected]
